ArticleACS omega2023
Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated from
Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Discovery of clocinizine as a potential oral drug against Schistosoma mansoni infection.Scientific reports · 2025Article
- Anthelmintic Potential of Conjugated Long-Chain Fatty Acids Isolated from the Bioluminescent MushroomJournal of natural products · 2025Article
- Anthelmintic activity of 1,10-phenanthroline-5,6-dione-based metallodrugs.Scientific reports · 2025Article
- Article
- Antihistamines HACS omega · 2024Article
- Article
- The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs.Future medicinal chemistry · 2024Article
- Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis, a parasitic disease affecting nearly 250 million individuals globally, poses a significant health challenge. With praziquantel being the sole available treatment and its limited efficacy in early stage infections, the identification of novel bioactive compounds becomes imperative. This study examines the potential of dehydrodieugenol B (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.